A Panel Discussion of Critical New Advances in Pancreatic Cancer from ASCO-GI to the 2019 ASCO Annual Meeting

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 24, 2019
Expiration Date: July 24, 2020

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Pancreatic cancer treatment options has shown slow progress in the past few years, however, recent studies suggest there may be new options on the horizon. Expert faculty will review some of the most relevant data from the 2019 ASCO-GI and 2019 ASCO Annual Meeting, and explain how this data may be clinically applicable in future practice. In this activity, Dr. Bekaii-Saab and Dr. Wang-Gillam will provide highlights from some of the select poster sessions. In addition, faculty will share data analysis from two very important trials presented at ASCO 2019. The first was presented as a Plenary Session this year looking at PARP inhibitors in the maintenance setting of pancreatic cancer in patients (POLO Trial) as well as APACT: A Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma abstract data.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify therapeutic strategies for optimizing treatment in patients with metastatic pancreatic cancer in first-line, second-line, and maintenance settings
  • Summarize efficacy and safety data from clinical trials investigating emerging therapies, combination treatments, and novel targets in metastatic pancreatic cancer
  • Describe data and progress resulting from adjuvant and neo-adjuvant trials in resectable, localized pancreatic cancer


A Panel Discussion of Critical New Advances in Pancreatic Cancer from ASCO-GI to the 2019 ASCO Annual Meeting – Tanios Bekaii-Saab, MD, FACP, and Andrea Wang-Gillam, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through July 24, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic College of Medicine and Science
Program Co-Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Medical Director, Cancer Clinical Research Office
Section Chief and Vice-Chair
Division of Hematology/Oncology
Mayo Clinic
Phoenix, Arizona

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, and Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona.

Dr. Bekaii-Saab has authored or co-authored more than 350 peer reviewed publications, abstracts, and book chapters, including papers in such journals as Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Eileen M. O’Reilly, MD - Chairperson
Associate Director for Clinical Research
David M. Rubenstein Center for Pancreas Cancer
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Eileen M. O’Reilly received her medical degree at Trinity College (Dublin University) in her native Ireland. She completed her residency training in Ireland and her fellowship training at Memorial Sloan Kettering Cancer Center (MSK) in New York City. Dr. O’Reilly serves as the Associate Director for Clinical Research at the David M. Rubenstein Center for Pancreas Cancer at MSK, where she is also an Attending Physician. In addition, she is Professor of Medicine at Weill Cornell Medical College.

Nationally, Dr. O’Reilly is the Chair of the Alliance Cooperative Group Gastrointestinal Cancers Committee, and serves on the Scientific Advisory Board of the Pancreatic Cancer Action Network, NCCN Pancreas Panel, and is on the Board of the National Pancreas Foundation and ASCO IMT Committee. Her institutional responsibilities include Associate Chairpersonship of the MSK Institutional Review & Privacy Board (IRB), membership in the Research Council, Chair of the Continuing Medical Education (CME) Committee, and Chair of the Data and Safety Monitoring Committee (DSMC).

Dr. O’Reilly is the Principal Investigator of multiple phase I, II, and III trials in pancreas cancer and has authored/co-authored multiple articles, editorials, and book chapters. Her major research focus and clinical activities include pancreatic and hepatobiliary malignancies, and her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreas cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy. In addition, Dr. O’Reilly teaches and mentors oncology fellows, junior faculty, residents and house-staff, and has won numerous teaching and other awards.

Andrea Wang-Gillam, MD, PhD
Associate Professor
Clinical Director
GI Oncology Program
Washington University
St. Louis, Missouri

Dr. Andrea Wang-Gillam received her medical degree and PhD from the University of Arkansas College of Medicine. She completed her internship in internal medicine at the Cleveland Clinic Foundation, and her residency in internal medicine and fellowship in hematology/oncology from the University of Arkansas for Medical Sciences. She is an Associate Professor and the Clinical Director for the GI Oncology Program in the Division of Oncology at Washington University in St. Louis, Missouri.

Board certified in internal medicine and medical oncology, Dr. Wang-Gillam holds memberships in the American Society of Clinical Oncology, the American Pancreatic Cancer Association, and the American Association for Cancer Research. Her research focuses on novel therapy developments in pancreatic cancer, and she has developed several investigator-initiated studies in pancreatic cancer. She also has served as a principal investigator for multiple pancreatic cancer studies.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-19-018-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-018-107


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Tanios Bekaii-Saab has disclosed no relevant financial relationships.

Dr. Andrea Wang-Gillam has received honoraria related to formal advisory activities from Ipsen and Merrimack Pharmaceuticals, Inc.

Dr. Eileen O’Reilly has received consultant fees from Agios; Amgen Inc.; Antengene Corporation; Aptus Pharma Pvt. Ltd.; ASLAN Pharmaceuticals; Astellas Pharma US, Inc.; AstraZeneca; Bayer AG; Boston Scientific Corporation; Bristol-Myers Squibb Company; CARsgen Therapeutics; CASI; Celgene Corporation; CytomX Therapeutics, Inc.; Daiichi Sankyo Company Limited; Debiopharm Group; Delcath Systems, Inc.; Eisai Co., Ltd.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; Merck & Co., Inc.; Onxeo; PCI Biotech; Sanofi; SERVIER; Silenseed LTD; SillaJen Biotherapeutics; Sirtex; Vicus Therapeutics; and Yakult. She has received grant support related to research activities from Agios; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI; Celgene; Exelixis; Eli Lilly and Company; Incyte Corporation; F. Hoffmann-La Roche; Genentech, Inc.; Incyte Corporation, Inc.; MabVax Therapeutics Holdings, Inc.; MedImmune, LLC; Momenta Pharmaceuticals; Novartis; and OncoMed Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Ipsen, and Merck & Co., Inc

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of PartnersinPancreaticCancer.com.

©2020 MediCom Worldwide, Inc. All rights reserved